

Welcome to the HelloCUVITRU Free Trial Program

Stay true to yourself.

Start CUVITRU with confidence



#### What is CUVITRU® [Immune Globulin Subcutaneous (Human)] 20% Solution?

CUVITRU is a ready-to-use liquid medicine that is given under the skin (subcutaneously) to treat primary immunodeficiency (PI) in people 2 years and older.

#### **IMPORTANT SAFETY INFORMATION**

#### What is the most important information I need to know about CUVITRU?

CUVITRU can cause the following serious reactions:

- Severe allergic reactions causing difficulty in breathing or skin rashes
- · Decreased kidney function or kidney failure
- Blood clots in the heart, brain, lungs, or elsewhere in the body
- Severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting
- Dark colored urine, swelling, fatigue, or difficulty breathing





#### Here's what to expect from the Free Trial Program:



#### **Enroll**

Once you and your healthcare provider (HCP) decide to try CUVITRU and enroll in the HelloCUVITRU Free Trial Program, your HCP will start the enrollment process.

To be eligible for the HelloCUVITRU program, you must:

- 1. Be a patient 2 years of age or older with an ICD-10-verified diagnosis of primary immunodeficiency (PI).
- 2. Be a new patient not currently using CUVITRU and who has not previously enrolled in the HelloCUVITRU program. Additional terms apply.

#### What you need to do:

If you do not have epinephrine at home already, you will need to get a prescription from your HCP. As a safety measure, epinephrine needs to be on hand for your first free trial CUVITRU infusion.



#### Welcome call

## You will receive a welcome call from a HelloCUVITRU Free Trial Case Manager.

Your Case Manager will help you during the call:

- If you have not yet signed the HelloCUVITRU Form, your Case Manager will assist with that process
- Connects you with the specialty pharmacy, RxCrossroads, that will coordinate the shipment of your medication
- Connects you with a nurse from the Specialty Pharmacy Nursing Network (SPNN), who will help schedule your in-home administration training

#### What you need to do:

Keep an eye out for a call or voicemail from your Hello Case Manager. Note that this call may come from a number you do not recognize.

# 8

#### Start

A SPNN nurse will come to your home to administer your CUVITRU infusions and provide initial administration training.

This will include:

- How to set up the supplies and self-infuse CUVITRU
- How to optimize your CUVITRU infusion rate to lessen your infusion time or number of needlesticks

#### What you need to do:

Have your Infusion Checklist (included with this brochure) ready and make sure your SPNN nurse fills in the appropriate information.

#### After the HelloCUVITRU Free Trial Program:

If you and your HCP wish for you to continue on CUVITRU, you will need a prescription.

Since the insurance approval process can be lengthy, it's important that you follow up with your HCP office **prior to your last infusion** to allow enough time for this process.



### Accompanying Infusion Checklist

Use the Infusion Checklist with your SPNN nurse as you are learning how to administer CUVITRU.

Keep this checklist on hand.

Should you and your HCP decide for you to continue CUVITRU therapy, you will work with a different specialty pharmacy (SP) to manage your new prescription. As part of that process, your SP may provide you with a new nurse to help you formally onboard onto CUVITRU as ongoing therapy.

Plan to share the Infusion Checklist with your new specialty pharmacy nurse to help with the therapy onboarding process.

#### **IMPORTANT SAFETY INFORMATION (continued)**

#### Who should not use CUVITRU?

Do not use CUVITRU if you:

- Have had a severe allergic reaction to immune globulin or other blood products.
- Have a condition called selective (or severe) immunoglobulin A (IgA) deficiency.

#### What should I avoid while taking CUVITRU?

- CUVITRU can make vaccines (like measles/mumps/rubella or chickenpox vaccines) not work as well for you. Before you get any vaccines, tell your healthcare provider (HCP) that you take CUVITRU.
- Tell your HCP if you are pregnant, or plan to become pregnant, or if you are nursing.

#### **IMPORTANT SAFETY INFORMATION (continued)**

What are the possible or reasonably likely side effects of CUVITRU?

CUVITRU can cause serious side effects. If any of the following problems occur after starting CUVITRU, stop the infusion immediately and contact your HCP or call emergency services:

- Hives, swelling in the mouth or throat, itching, trouble breathing, wheezing, fainting or dizziness. These could be signs of a serious allergic reaction.
- Bad headache with nausea, vomiting, stiff neck, fever, and sensitivity to light. These could be signs of irritation and swelling of the lining around your brain.
- Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem.
- Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot.

Please see additional safety information throughout, <u>click here</u> for Information for Patients, including Warning about Blood Clots, and discuss with your HCP.

# **Hello**CUVITRU

#### Benefits of the HelloCUVITRU Free Trial Program



Allows you and your physician to determine if CUVITRU is right for you.



The entire cost of your first four (4) CUVITRU infusions are free, including the pump, supplies, and administration training. Everything will be shipped directly to your home.



Your SPNN nurse will help you administer your CUVITRU therapy and can work with you to optimize your therapy administration parameters.



Together, you can customize the number of infusion sites, the volume infused per site, and how fast and how often you infuse.

#### CUVITRU has the fastest subQ infusion rates and fewest needlesticks.

In the clinical study of CUVITRU,\* the average duration of once-weekly infusions was less than 1 hour (0.95 hours; range, 0.2-6.4 hours) and most infusions (84.9%) used 1 to 2 infusion sites.

So whether you prefer infusions that take less than an hour or fewer needlesticks, CUVITRU may be the subcutaneous immunoglobulin (subQ) of choice.<sup>†</sup>

\*CUVITRU was studied in 77 people with primary immunodeficiency (PI) ≥2 years of age in North America. The main goal of this study was to measure how many acute serious bacterial infections (ASBIs) were experienced over the course of 1 year. ASBIs are short-term but serious infections caused by bacteria that require immediate medical care.

#### For additional information, contact HelloCUVITRU at 1.866.888.0660.

#### **IMPORTANT SAFETY INFORMATION (continued)**

What are the possible or reasonably likely side effects of CUVITRU? (continued)

CUVITRU can cause serious side effects. If any of the following problems occur after starting CUVITRU, stop the infusion immediately and contact your HCP or call emergency services:

- Brown or red urine, fast heart rate, yellow skin or eyes. These could be signs of a liver or blood problem.
- Chest pain or trouble breathing, or blue lips or extremities. These could be signs of a serious heart or lung problem.
- Fever over 100°F. This could be sign of an infection.

The following one or more possible side effects may occur at the site of infusion. These generally go away within a few hours, and are less likely after the first few infusions.

Mild or moderate pain

Redness

Itching

The most common side effects that may occur are:

Headache

Nausea

Fatigue

• Diarrhea

Vomiting

These are not all the possible side effects. Talk to your HCP about any side effect that bothers you or that does not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. <u>Visit www.fda.gov/medwatch</u>, or call 1-800-FDA-1088.

Please see additional safety information throughout, <u>click here</u> for Information for Patients, including Warning about Blood Clots, and discuss with your HCP.

Learn more about starting CUVITRU at <u>cuvitru.com/starting-cuvitru</u>.



<sup>†</sup> If the first 2 infusions at 10-20 mL/hour/site are well-tolerated, your next infusions can begin at the maximum tolerated rate of 60 mL/hour/site.